Search Results - katherine+nyswaner

1 Results

Sort By:

LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression

This technology includes the use of LZK and DLK inhibitors to be used for the treatment of head and neck squamous cell carcinoma (HNSCC) or lung squamous cell carcinoma (LSCC). Specifically, we demonstrate that inhibitors that can be repurposed to target LZK suppresses LZK kinase-dependent stabilization of MYC and activation of the PI3K/AKT pathway....

Published: 8/12/2024 | Inventor(s): John Brognard, Rolf Swenson, Amy Funk, Carolyn Hitko, Katherine Nyswaner

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology